VSTM – Verastem Oncology

1. Executive Summary

Verastem Oncology is transitioning from a late-stage developer into a commercial oncology company focused on RAS/MAPK pathway-driven cancers. The key turning point was the FDA accelerated approval in May 2025 of the co-packaged combo Avmapki Fakzynja (avutometinib + defactinib) for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).

In the first full quarter after launch (Q3 2025), Verastem reported $11.2M in net product revenue from Avmapki Fakzynja and ended the quarter with $137.7M in cash, cash equivalents and investments, guiding cash runway into the second half of 2026 assuming product revenue and warrant exercises.

Beyond the initial LGSOC indication, the strategy is to:

• Solidify the U.S. launch in KRAS-mutant LGSOC and execute the RAMP 301 Phase 3 trial as the confirmatory study for the accelerated approval.
• Expand the avutometinib/defactinib platform into pancreatic cancer (RAMP 205) and KRAS G12C NSCLC (RAMP 203, in collaboration with Amgen’s sotorasib).
• Develop VS-7375, an oral KRAS G12D ON/OFF inhibitor, currently in a U.S. Phase 1/2a study with encouraging early safety and tumor shrinkage signals.

2. Company Overview

Verastem, Inc., doing business as Verastem Oncology, is a U.S. biopharmaceutical company founded in 2010 and focused on developing small-molecule therapies for RAS/MAPK pathway-driven cancers. The company is headquartered in Massachusetts and is part of the NASDAQ Biotechnology Index.

The current strategy is centered on:

• RAF/MEK inhibition via avutometinib.
• FAK inhibition via defactinib.
• KRAS G12D inhibition via VS-7375, licensed from GenFleet.

Management is led by CEO Brian Stuglik, who has been in the role since 2019, with a team experienced in oncology development and commercialization.

3. Commercial Product & Pipeline

3.1 Avmapki Fakzynja (avutometinib + defactinib) – LGSOC

The co-packaged regimen Avmapki Fakzynja combines:

• Avutometinib – an oral RAF/MEK clamp (kinase inhibitor).
• Defactinib – an oral FAK inhibitor.

In May 2025, the FDA granted accelerated approval for the combination for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. The decision was based primarily on the single-arm RAMP 201 study showing robust and durable responses in this high-need population.

3.2 RAMP 301 – LGSOC confirmatory trial

RAMP 301 is the randomized Phase 3 confirmatory trial comparing avutometinib + defactinib vs investigator’s choice in relapsed/refractory LGSOC. Enrollment of the originally planned 270 patients has been completed, and an independent data monitoring committee has recommended a one-time increase of 29 additional patients, for a target enrollment of 299 with full enrollment expected in Q1 2026.

The outcome of RAMP 301 is critical: a positive result would support conversion from accelerated to full approval and potentially strengthen Verastem’s commercial position in LGSOC.

3.3 RAMP 205 – Pancreatic cancer

RAMP 205 is a Phase 1b/2 trial evaluating avutometinib + defactinib + gemcitabine/nab-paclitaxel in front-line metastatic pancreatic ductal adenocarcinoma (PDAC). The trial is supported by a PanCAN Therapeutic Accelerator Award, and the combo holds FDA Orphan Drug Designation for pancreatic cancer.

3.4 RAMP 203 – KRAS G12C NSCLC

RAMP 203 evaluates avutometinib + sotorasib (Amgen’s Lumakras) ± defactinib in patients with KRAS G12C-mutant NSCLC, including treatment-naïve and those who have progressed on prior G12C inhibitor therapy. The combination has received Fast Track designation from the FDA.

3.5 VS-7375 – Oral KRAS G12D (ON/OFF) inhibitor

VS-7375 (GFH375 in China) is a potent, selective oral KRAS G12D dual ON/OFF inhibitor licensed from GenFleet Therapeutics.

• U.S. IND cleared in April 2025; Phase 1/2a study VS-7375-101 initiated mid-2025 in KRAS G12D-mutant solid tumors.
• Early dose-escalation data: 400 mg and 600 mg monotherapy doses cleared with no dose-limiting toxicities and generally mild GI profile. Among efficacy-evaluable patients, most showed tumor reduction and remained on treatment.
• A combination cohort with cetuximab has been opened, including colorectal cancer patients.

4. Financial Situation (Q3 2025 snapshot)

According to the Q3 2025 financial results release, Verastem reported:

• Net product revenue: $11.2M (Avmapki Fakzynja) – first full commercial quarter.
• Total operating expenses: ~$52.0M for the quarter.
• GAAP net loss: ~$98.5M for Q3 2025 (−$1.35 per share).
• Non-GAAP adjusted net loss: ~$39.4M (−$0.54 per share).
• Cash, cash equivalents & investments: $137.7M as of Sept 30, 2025.
• Runway guidance: expected to extend into 2H 2026, assuming revenue contribution and exercise of cash warrants.

5. Key Catalysts (approx. 6–24 months)

Catalyst timing is approximate and based on public guidance where available. Always cross-check with the latest company presentations and filings.

6. Management & Execution Considerations

Verastem has gone through multiple strategic shifts in the past decade, including setbacks in defactinib’s earlier development programs. The current team under CEO Brian Stuglik has repositioned the company around:

• RAS/MAPK-driven cancers with a clear mechanistic rationale.
• A targeted first commercial niche (KRAS-mutant recurrent LGSOC).
• Partnerships (Amgen, GenFleet) to leverage external assets and capabilities.

For traders and investors watching execution:

• Monitor quarterly Avmapki Fakzynja revenue trends versus operating expense trajectory.
• Track management’s guidance and delivery on RAMP 301, RAMP 203/205 and VS-7375 milestones.
• Watch for any ex-U.S. partnering deals that could bring non-dilutive capital.

7. Scenario Framework (Purely Educational)

7.1 Upside scenario (educational)

• LGSOC launch scales faster than expected with strong uptake in KRAS-mutant patients.
• RAMP 301 confirmatory data are clearly positive → full approval and label stability.
• RAMP 203 and 205 generate convincing proof-of-concept in NSCLC/PDAC.
• VS-7375 shows differentiated efficacy and tolerability in KRAS G12D tumors.
• Company secures ex-U.S. deals that bring upfront payments and future royalties.

7.2 Base case (balanced view)

• LGSOC launch progresses but with the typical adoption curve for a new targeted therapy in a rare setting.
• RAMP 301 reads out with clinically meaningful benefit but not “blow-out” data.
• VS-7375 early data are encouraging but need expansion cohorts and longer follow-up.
• Additional capital is eventually needed but timed after key value inflection points (for example, post-interim VS-7375 data).

7.3 Downside / red-flag scenario

• Commercial risk: LGSOC uptake disappoints (competition, access, toxicity, or real-world efficacy issues) and revenue remains well below expectations.
• Clinical risk: RAMP 301 fails to confirm benefit → risk to the accelerated approval.
• Pipeline risk: VS-7375 or RAMP 203/205 generate safety concerns or lack convincing efficacy → pipeline devaluation.
• Financing/dilution: high burn rate and limited cash runway lead to sizeable equity raises, potentially at unfavorable prices.
• Regulatory risk: evolving FDA views on accelerated approvals and oncology endpoints could impact the risk/benefit assessment.

8. Bottom Line (Educational Summary)

Verastem Oncology today sits at the intersection of:

• A first commercial asset in a high-need niche (KRAS-mutant recurrent LGSOC).
• A RAS/MAPK pipeline (RAMP 203/205, VS-7375) that can materially expand the addressable market.
• A non-trivial cash burn profile that makes execution and timing of catalysts critical.

This report is intended purely as a structured, transparent summary of public information, not as financial advice.

9. Sources, Tools & Disclaimers

9.1 Main information sources

• Verastem Oncology – Q3 2025 Financial Results & Business Updates (Business Wire, Nov 4 2025).
• Verastem corporate pipeline page – avutometinib, defactinib, VS-7375 and RAMP trials.
• FDA approval and background on Avutometinib/Defactinib (Avmapki Fakzynja) for KRAS-mutant recurrent LGSOC.
• Verastem press releases on VS-7375 (IND clearance and early clinical data).
• Public price/market cap snapshots from reputable market data providers (Nasdaq, Kraken, CompaniesMarketCap, Public.com).

9.2 Tools and reference platforms